Prediction of docetaxel response in human breast cancer by gene expression profiling.

PURPOSE Docetaxel is one of the most effective anticancer drugs available in the treatment of breast cancer. Nearly half of the treated patients, however, do not respond to chemotherapy and suffer from side effects. The ability to reliably predict a patient's response based on tumor gene expression will improve therapeutic decision making and save patients from unnecessary side effects. PATIENTS AND METHODS A total of 44 breast tumor tissues were sampled by biopsy before treatment with docetaxel, and the response to therapy was clinically evaluated by the degree of reduction in tumor size. Gene expression profiling of the biopsy samples was performed with 2,453 genes using a high-throughput reverse transcriptase polymerase chain reaction technique. Using genes differentially expressed between responders and nonresponders, a diagnostic system based on the weighted-voting algorithm was constructed. RESULTS This system predicted the clinical response of 26 previously unanalyzed samples with over 80% accuracy, a level promising for clinical applications. Diagnostic profiles in nonresponders were characterized by elevated expression of genes controlling the cellular redox environment (ie, redox genes, such as thioredoxin, glutathione-S-transferase, and peroxiredoxin). Overexpression of these genes protected cultured mammary tumor cells from docetaxel-induced cell death, suggesting that enhancement of the redox system plays a major role in docetaxel resistance. CONCLUSION These results suggest that the clinical response to docetaxel can be predicted by gene expression patterns in biopsy samples. The results also suggest that one of the molecular mechanisms of the resistance is activation of a group of redox genes.

[1]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Powis,et al.  Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues , 2004, Cancer Chemotherapy and Pharmacology.

[3]  Y. Miyoshi,et al.  Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer , 2001, International journal of cancer.

[4]  J. Yodoi,et al.  Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. , 1995, Cancer research.

[5]  L. Walker,et al.  Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. , 2002, Clinical breast cancer.

[6]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[7]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[8]  H. Bear,et al.  Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. , 2003, The Surgical clinics of North America.

[9]  Nello Cristianini,et al.  Support vector machine classification and validation of cancer tissue samples using microarray expression data , 2000, Bioinform..

[10]  M. Kavallaris,et al.  The role of β-tubulin isotypes in resistance to antimitotic drugs , 2001 .

[11]  H. Nakamura,et al.  Redox regulation of cellular activation. , 1997, Annual review of immunology.

[12]  C. Stein Mechanisms of action of taxanes in prostate cancer. , 1999, Seminars in oncology.

[13]  M. Piccart,et al.  A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[15]  J. Yodoi,et al.  Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. , 1996, The Journal of clinical investigation.

[16]  T. Takayama,et al.  Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. , 1996, Cancer research.

[17]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[18]  S. Ishii,et al.  Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data , 2003, Genome Biology.

[19]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[20]  Shinzaburo Noguchi,et al.  Molecular classification of primary breast tumors possessing distinct prognostic properties. , 2002, Human molecular genetics.

[21]  Y. Nakanishi,et al.  Immunohistochemical expression of glutathione S‐transferase‐π can predict chemotherapy response in patients with nonsmall cell lung carcinoma , 1996, Cancer.

[22]  D. Wickerham,et al.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[24]  Elias S. J. Arnér,et al.  Physiological functions of thioredoxin and thioredoxin reductase. , 2000, European journal of biochemistry.

[25]  M. Monden,et al.  Mutational analysis of the class I β‐tubulin gene in human breast cancer , 2002 .

[26]  M. Holland,et al.  Transcript Abundance in Yeast Varies over Six Orders of Magnitude* , 2002, The Journal of Biological Chemistry.

[27]  J. Blumenstock,et al.  Using gene expression ratios to predict outcome among patients with mesothelioma. , 2003, Journal of the National Cancer Institute.

[28]  G. Filomeni,et al.  Cell signalling and the glutathione redox system. , 2002, Biochemical pharmacology.

[29]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[30]  A. Holmgren,et al.  Up‐regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma , 2001, International journal of cancer.

[31]  B. Trock,et al.  Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer , 1999 .

[32]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[33]  Kikuya Kato,et al.  Adaptor-tagged competitive PCR: a novel method for measuring relative gene expression. , 1997, Nucleic acids research.